OPTIMIZE PRO CLINICAL STUDY INTERIM ANALYSIS EXCEPTIONAL DATA

Optimize PRO study investigators use the cusp overlap technique and a prespecified conduction disturbance pathway, both of which have contributed to excellent clinical outcomes.



87.1%

OF PATIENTS TREATED WITH EVOLUT™ PRO+ SYSTEM

8.8%

PERMANENT PACEMAKER RATE AT 30 DAYS[1]

1 DAY

MEDIAN LENGTH OF STAY[1]

0 DEATHS

AND DISABLING STROKES AT 30 DAYS[1]

0 POP-OUTS[1]

0%

MODERATE/SEVERE PVL AT DISCHARGE[1]

(19.6% mild PVL at discharge)

8.1 mm Hg

GRADIENT AT DISCHARGE[1]

This is an interim analysis of 171 patients (71 roll-in and 100 main cohort). At the conclusion of the study, more than 600 patients will have been evaluated.

Medtronic

Reference
[1] Grubb K, et al. An Optimized TAVR Care Pathway Using Evolut PRO and PRO+ Early Results from the Optimize PRO Study. Presented at SCAI 2021.

See the CoreValve™ Evolut™ R, the CoreValve™ Evolut™ PRO and the Evolut™ PRO+ device manuals for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu.

For applicable products, consult instructions for use on manuals.medtronic.com. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.

The commercial name of the Evolut™ R device is Medtronic CoreValve™ Evolut™ R System, the commercial name of the Evolut™ PRO device is Medtronic CoreValve™ Evolut™ PRO System, and the commercial name of the Evolut™ PRO+ device is Medtronic Evolut™ PRO+ System.

Medtronic

Europe
Medtronic International Trading Sàrl.
Route du Molliau 31
Case postale
CH-1131 Tolochenaz
www.medtronic.eu
Tel: +41 (0)21 802 70 00
Fax: +41 (0)21 802 79 00

medtronic.eu